18 research outputs found
MUC1 epithelial mucin (CD227) is expressed by activated dendritic cells
The MUC1 mucin (CD227) is a cell surface mucin originally thought to be restricted to epithelial tissues. We report that CD227 is expressed on human blood dendritic cells (DC) and monocyte-derived DC following in vitro activation. Freshly isolated murine splenic DC had very low levels of CD227; however, all DC expressed CD227 following in vitro culture. In the mouse spleen, CD227 was seen on clusters within the red pulp and surrounding the marginal zone in the white pulp. Additionally, we confirm CD227 expression by activated human T cells and show for the first time that the CD227 cytoplasmic domain is tyrosine-phosphorylated in activated T cells and DC and is associated with other phosphoproteins, indicating a role in signaling. The function of CD227 on DC and T cells requires further elucidation
MUC1 cytoplasmic tail detection using CT33 polyclonal and CT2 monoclonal antibodies in breast and colorectal tissue
The immunohistochemical detection (IHC)
of MUC1-CT employing a polyclonal antibody (CT33)
in relation to CT2 monoclonal antibody (MAb) was
analyzed. Western blot (WB) was used to determine the
molecular mass of CT. Materials and methods: we
studied 163 breast and 89 colorectal cancer specimens,
10 breast and 14 colorectal benign conditions, and 12
breast and 20 colorectal normal samples. From each
tumor sample, subcellular fractions were obtained and
analyzed by SDS-PAGE and WB. A nonparametric
statistical analysis was employed; data were
standardized and a Kendall-Tau correlation was applied.
Results: by IHC, 146/163 (90%) and 151/163 (93%) of
breast cancer were positive with CT33 and CT2,
respectively; a statistically significant correlation was
obtained (t=0.5199). Seven out of ten (70%) benign
breast specimens were positive with CT33 while all
samples stained with CT2; in normal breast sample
tissues, all were positive with both Abs. In colorectal
cancer samples, both antibodies stained 47/89 (53%)
samples; CT2 reacted in 13/14 (93%) of benign samples
while CT33 showed a positive reaction in 9/14 (64%) of
benign specimens. In normal samples, CT2 showed
staining in 17/20 (85%) of samples and CT33 was
reactive in 12/20 (60%). By WB, in breast and colorectal
cancer samples, similar results were obtained with both
antibodies: a main band at about 30kDa which represents
the smaller subunit.
Conclusion: CT33 polyclonal antibody has
demonstrated its efficacy to detect MUC1 in breast and
colorectal cancer tissues with similar reactivity to CT2.
It is worthwhile to affirm that CT33 is a good indicator
of MUC1 expression